Tvardi Therapeutics is expected to report zero revenue and a consensus EPS of -$0.51 for the third quarter of 2026, with the stock currently trading at approximately $0.96 against an average analyst price target of $8.17. Investors are primarily focused on upcoming topline data from the Phase 1b/2 trial of lead candidate TTI-101 in hepatocellular carcinoma, which is anticipated by the end of 2026.
The company’s cash runway is also under significant scrutiny, as previous guidance suggests current funding will only support operations through the fourth quarter of 2026. Consequently, management’s updates on liquidity, potential financing strategies, and the clinical progress of its next-generation STAT3 inhibitor, TTI-109, will be critical for maintaining shareholder confidence during this pre-revenue stage.